Idalman (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks AT1 receptors for angiotensin II, a hormone that narrows blood vessels and stimulates aldosterone release. Blocking these receptors prevents vasoconstriction and reduces fluid retention, leading to lower peripheral resistance and decreased blood pressure.

The appropriate dose of Idalman is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any concomitant conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of olmesartan medoxomil in pregnancy has not been established, and it is generally avoided because of potential fetal harm. Information on use while breastfeeding is limited, so the medication should be used only if the potential benefit justifies the possible risk to the infant.

To request Idalman, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, olmesartan (an ARB) provides similar blood‑pressure reduction but is less likely to cause cough. Unlike calcium‑channel blockers, it works by blocking the renin‑angiotensin system rather than relaxing vascular smooth muscle directly. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Idalman tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Idalman is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, although rare, include angioedema (swelling of the face, lips, tongue), severe hyperkalemia, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden loss of kidney function, or markedly elevated potassium levels.

Idalman should be avoided in patients with known hypersensitivity to olmesartan or any component of the formulation, in those with severe hepatic impairment, and in pregnant women. Caution is also advised for individuals with significant renal dysfunction or elevated serum potassium.